SG11202102651SA - Farnesoid x receptor agonists and uses thereof - Google Patents

Farnesoid x receptor agonists and uses thereof

Info

Publication number
SG11202102651SA
SG11202102651SA SG11202102651SA SG11202102651SA SG11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA
Authority
SG
Singapore
Prior art keywords
farnesoid
receptor agonists
agonists
receptor
Prior art date
Application number
SG11202102651SA
Other languages
English (en)
Inventor
Nicholas D Smith
Steven P Govek
Karensa L Douglas
Andiliy G Lai
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of SG11202102651SA publication Critical patent/SG11202102651SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102651SA 2018-09-18 2019-09-17 Farnesoid x receptor agonists and uses thereof SG11202102651SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862733006P 2018-09-18 2018-09-18
US201862733004P 2018-09-18 2018-09-18
US201962881560P 2019-08-01 2019-08-01
PCT/US2019/051603 WO2020061113A1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202102651SA true SG11202102651SA (en) 2021-04-29

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102651SA SG11202102651SA (en) 2018-09-18 2019-09-17 Farnesoid x receptor agonists and uses thereof

Country Status (16)

Country Link
US (3) US11084817B2 (fr)
EP (1) EP3852748A4 (fr)
JP (1) JP2022500392A (fr)
KR (1) KR20210076910A (fr)
CN (1) CN113056271A (fr)
AU (1) AU2019344903A1 (fr)
BR (1) BR112021004919A2 (fr)
CA (1) CA3112411A1 (fr)
CL (1) CL2021000632A1 (fr)
IL (1) IL281475A (fr)
MA (1) MA53665A (fr)
MX (1) MX2021003110A (fr)
PH (1) PH12021550605A1 (fr)
SG (1) SG11202102651SA (fr)
TW (1) TWI833805B (fr)
WO (1) WO2020061113A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269065B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
SG11202102651SA (en) 2018-09-18 2021-04-29 Metacrine Inc Farnesoid x receptor agonists and uses thereof
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
US20230147756A1 (en) * 2020-03-18 2023-05-11 Metacrine, Inc. Crystalline forms of a farnesoid x receptor agonist
AR121597A1 (es) * 2020-03-18 2022-06-22 Metacrine Inc Formulaciones de un agonista del receptor farnesoide x
CA3172205A1 (fr) * 2020-03-18 2021-09-23 Metacrine, Inc. Agonistes du recepteur de farnesoide x pour le traitement d'une maladie
EP4277622A1 (fr) 2021-01-14 2023-11-22 ENYO Pharma Effet synergique d'un agoniste de fxr et d'ifn pour le traitement d'une infection par le virus de l'hépatite b
WO2022229302A1 (fr) 2021-04-28 2022-11-03 Enyo Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011757A (es) 1999-05-17 2002-06-04 Novo Nordisk As Antagonistas / agonistas inversos del glucagon.
WO2000071518A2 (fr) 1999-05-25 2000-11-30 Sepracor, Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
WO2001092226A1 (fr) 2000-05-25 2001-12-06 Sepracor, Inc. Composes analgesiques heterocycliques et technique d'utilisation de ceux-ci
KR20030029978A (ko) 2000-09-25 2003-04-16 액테리온 파마슈티칼 리미티드 말라리아에 유용한 치환된 아미노-아자-사이클로알칸
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004026823A1 (fr) 2002-09-20 2004-04-01 Pfizer Products Inc. Ligands d'amides et de sulfonamides du recepteur oestrogenique
WO2004046162A2 (fr) 2002-11-14 2004-06-03 The Scripps Research Institute Agonistes fxr non steroidiques
AU2003298654A1 (en) 2002-11-15 2004-06-15 The Salk Institute For Biological Studies Structure of the farnesoid x receptor ligand binding domain and methods of use therefor
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
ES2375134T3 (es) 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
WO2005058822A1 (fr) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Cycloalcanes amines substitues
US20050239751A1 (en) 2004-03-26 2005-10-27 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
KR20080098548A (ko) 2006-03-28 2008-11-10 노파르티스 아게 Ｇ 단백질 관련 질환의 치료를 위한 아미드 유도체 및 그의투여
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (fr) 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
KR20100098534A (ko) 2007-12-19 2010-09-07 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
WO2010001869A1 (fr) 2008-06-30 2010-01-07 武田薬品工業株式会社 Composé de benzène tétrasubstitué et son utilisation
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20120115869A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tetrazole derivatives
WO2011008915A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridines inhibiteurs de kinases
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
LT2688403T (lt) 2011-03-23 2017-07-25 Trevena, Inc. Opioidų receptorių ligandai ir jų panaudojimo bei gamybos būdai
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
US9492763B2 (en) 2011-07-13 2016-11-15 M. Technique Co., Ltd. Method for producing microparticles having controlled crystallite diameter
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
WO2015138986A1 (fr) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Agonistes fxr et leurs procédés de fabrication et d'utilisation
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
WO2016116054A1 (fr) 2015-01-22 2016-07-28 Xiamen University Modulateurs du récepteur farnésoïde x et leurs méthodes d'utilisation
AU2016233579A1 (en) 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017018751A1 (fr) 2015-07-24 2017-02-02 동국대학교 산학협력단 Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
WO2017049172A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350164A4 (fr) * 2015-09-16 2019-03-27 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
MX2018003388A (es) * 2015-09-16 2019-01-31 Metacrine Inc Agonistas del receptor farnesoide x y usos de los mismos.
JP2018532772A (ja) 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
JP6889151B2 (ja) 2016-03-31 2021-06-18 株式会社Adeka 感光性組成物及び新規化合物
WO2018170167A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2018170165A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
IL269065B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (fr) 2018-09-17 2020-03-26 엘지전자 주식회사 Procédé et dispositif sans fil pour gérer une session de pdu dans une communication mobile 5g
AU2019344905A1 (en) 2018-09-18 2021-04-29 Metacrine, Inc. Crystalline forms of a farnesoid X receptor agonist
WO2020061114A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
WO2020061112A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2020061116A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20220056019A1 (en) 2018-09-18 2022-02-24 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061118A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
SG11202102651SA (en) 2018-09-18 2021-04-29 Metacrine Inc Farnesoid x receptor agonists and uses thereof
CA3172205A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Agonistes du recepteur de farnesoide x pour le traitement d'une maladie
US20230147756A1 (en) 2020-03-18 2023-05-11 Metacrine, Inc. Crystalline forms of a farnesoid x receptor agonist
AR121597A1 (es) 2020-03-18 2022-06-22 Metacrine Inc Formulaciones de un agonista del receptor farnesoide x

Also Published As

Publication number Publication date
JP2022500392A (ja) 2022-01-04
TWI833805B (zh) 2024-03-01
US20210395253A1 (en) 2021-12-23
AU2019344903A1 (en) 2021-05-13
MA53665A (fr) 2021-07-28
BR112021004919A2 (pt) 2021-06-01
CL2021000632A1 (es) 2021-07-23
US20230382913A1 (en) 2023-11-30
IL281475A (en) 2021-04-29
KR20210076910A (ko) 2021-06-24
US20200102308A1 (en) 2020-04-02
PH12021550605A1 (en) 2021-10-04
WO2020061113A1 (fr) 2020-03-26
CA3112411A1 (fr) 2020-03-26
CN113056271A (zh) 2021-06-29
US11773094B2 (en) 2023-10-03
EP3852748A1 (fr) 2021-07-28
TW202024052A (zh) 2020-07-01
US11084817B2 (en) 2021-08-10
MX2021003110A (es) 2021-05-13
EP3852748A4 (fr) 2022-05-18

Similar Documents

Publication Publication Date Title
IL269065A (en) Paranoid X receptor agonists and uses thereof
IL269068A (en) Paranoid X receptor agonists and uses thereof
IL281475A (en) Paranoid X receptor agonists and uses thereof
HK1257751A1 (zh) 類法尼醇x受體激動劑及其用途
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
IL281471A (en) Farnesoid x receptor agonists and uses thereof
IL267288B (en) glp-1 receptor agonists and their use
IL281474A (en) Farnesoid x receptor agonists and uses thereof
EP3350166A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350164A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350158A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
SG11202103609YA (en) T-cell receptors and uses thereof
IL277144A (en) Adenosine receptor antagonists and uses thereof
EP3594221A4 (fr) Antagoniste du récepteur gpr84 et son utilisation
GB201817943D0 (en) Galanin-2 receptor agonists